Butidrine
Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Betabloc, Butidrate, Recetan |
| Other names | Butedrine; Butydrine; Hydrobutamine; Idrobutamine |
| Drug class | Beta blocker |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID |
|
| ChemSpider |
|
| UNII |
|
| ChEBI |
|
| ChEMBL |
|
| CompTox Dashboard (EPA) |
|
| Chemical and physical data | |
| Formula | C16H25NO |
| Molar mass | 247.382 g·mol−1 |
| 3D model (JSmol) |
|
| |
InChI
| |
Butidrine (INNTooltip International Nonproprietary Name), sold under the brand names Betabloc, Butidrate, and Recetan among others, is a beta blocker (or β-adrenergic receptor antagonist) related to pronethalol[1] and propranolol[2] that was developed in the 1960s.[3][4] It is not cardioselective (i.e., is not selective for the β1-adrenergic receptor over the β2-adrenergic receptor).[5] It has membrane stabilizing activity but no intrinsic sympathomimetic activity (i.e., partial agonist activity).[6] Similarly to certain other beta blockers, butidrine additionally possesses local anesthetic properties.[7]
References
- ^ Bristol JA (1986). Cardiovascular drugs. John Wiley & Sons, Incorporated. p. 111. ISBN 978-0-471-09228-5.
- ^ Drug Metabolism Reviews. Marcel Dekker. 1972.
- ^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 58–. ISBN 978-94-011-4439-1.
- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 197–. ISBN 978-1-4757-2085-3.
- ^ Sokabe, Hirofumi (1985). "A new classification of β-adrenoceptor blocking drugs". Trends in Pharmacological Sciences. 6: 107–109. doi:10.1016/0165-6147(85)90051-3.
- ^ Fitzgerald JD (1969). "Perspectives in adrenergic beta-receptor blockade". Clin Pharmacol Ther. 10 (3): 292–306. doi:10.1002/cpt1969103292. PMID 4894830.
- ^ Charlier R (1971). Antianginal drugs: pathophysiological, haemodynamic, methodological, pharmacological, biochemical and clinical basis for their use in human therapeutics. Springer-Verlag. ISBN 978-3-540-05365-1.
- v
- t
- e
- See also: Receptor/signaling modulators
- Dopaminergics
- Serotonergics
- Monoamine reuptake inhibitors
- Monoamine releasing agents
- Monoamine metabolism modulators
- Monoamine neurotoxins
